# US 2024/0207229 A1 · Cocrystalline forms of a bruton's tyrosine kinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0207229 A1
- Document ID: US20240207229A1
- Status: Published application
- Kind: A1
- Application number: 18/555,467
- Filed: 2022-05-11
- Published: 2024-06-27
- Earliest claimed: 2021-05-14
- Assignees: Loxo Oncology, Inc.
- Applicants: Loxo Oncology, Inc.
- Inventors: David Andrew COATES; Lori Raquel HILDEN
- Web page: https://patentgrep.com/patent/US20240207229A1

## CPC

- A61K 31/415: 1,2-Diazoles
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- C07C 55/14: Adipic acid
- C07C 61/06: Saturated compounds having a carboxyl group bound to a five-membered ring
- C07D 231/38: Nitrogen atoms (nitro radicals C07D231/16)
- C07C 2601/08: the ring being saturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are cocrystalline forms including BTK-I useful in the treatment and prevention of diseases which can be treated with a BTK inhibitor, including BTK-associated diseases and disorders, characterizations, and methods of making these cocrystalline forms.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A crystalline form of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide comprising the following formula:

### Claim 36 (depends on 35)

The crystalline form of claim 35, having an X-ray powder diffraction (XRPD) pattern comprising an XRPD peak at 2-theta angle of 18.7°±0.2°.

### Claim 37 (depends on 36)

The crystalline form of claim 36, having an X-ray powder diffraction (XRPD) pattern further comprising one or more XRPD peaks at 2-theta angles of 8.1°±0.2°, 10.4°±0.2°, 11.7°±0.2°, 12.1°±0.2°, 14.2°±0.2°, 15.1°±0.2°, 17.0°±0.2°, 17.3°±0.2°, 18.1°±0.2°, 19.2°±0.2°, 19.9°±0.2°, 20.4°±0.2°, 20.9°±0.2°, 21.6°±0.2°, 22.1°±0.2°, 23.7°±0.2°, 24.3°±0.2°, 24.8°±0.2°, 25.5°±0.2°, 26.1°±0.2°, 27.2°±0.2°, 27.4°±0.2°, 28.3°±0.2°, or 29.8°±0.2.

### Claim 38 (depends on 36)

The crystalline form of claim 36, having an X-ray powder diffraction (XRPD) pattern comprising XRPD peaks at 2-theta angle of 18.7°±0.2°, 17.0°±0.2°, and 21.6°±0.2°.

### Claim 39 (depends on 36)

The crystalline form of claim 36, having an X-ray powder diffraction (XRPD) pattern comprising XRPD peaks at 2-theta angle of 18.7°±0.2°, 14.2°±0.2°, 17.0°±0.2°, and 21.6°±0.2°.

### Claim 40 (depends on 35)

A pharmaceutical composition comprising the crystalline form of claim 35 and a pharmaceutically acceptable carrier, diluent, and/or excipient.

### Claim 41 (depends on 40)

The pharmaceutical composition of claim 40, comprising one or more polymers selected from the group consisting of polyvinylpyrrolidone vinyl acetate (PVP-VA), hydroxypropylmethylcellulose (HPMC) or hydroxypropylmethylcellulose acetate succinate (HPMCAS).

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the HPMCAS is selected from the group consisting of HPMCAS-L, HPMCAS-M, and HPMCAS-H.

### Claim 43 (depends on 35)

A method of treating a Bruton's Tyrosine Kinase (BTK)-associated cancer in a patient in need thereof, comprising administering to the patient an effective amount of the crystalline form of claim 35.

### Claim 44 (depends on 43)

The method of claim 43, wherein the BTK-associated cancer is selected from B-cell malignancy, B-cell lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, mantle cell lymphoma, follicular lymphoma, hairy cell leukemia, B-cell non-Hodgkin lymphoma, B-cell prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and multiple myeloma.

### Claim 45 (depends on 44)

The method of claim 44, wherein the BTK-associated cancer is chronic lymphocytic leukemia.

### Claim 46 (depends on 44)

The method of claim 44, wherein the BTK-associated cancer is small lymphocytic lymphoma.

### Claim 47 (depends on 44)

The method of claim 44, wherein the BTK-associated cancer is mantle cell lymphoma.

### Claim 48 (depends on 35)

A method of treating multiple sclerosis in a patient in need thereof, comprising administering to the patient an effective amount of the crystalline form of claim 35.

### Claim 49 (depends on 35)

A method of treating arthritis in a patient in need thereof, comprising administering to the patient an effective amount of the crystalline form of claim 35.

### Claim 50 (depends on 49)

The method of claim 49, wherein the arthritis is rheumatoid arthritis.

### Claim 51 (depends on 35)

A process for preparing the crystalline form of claim 35, comprising:
mixing (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide and adipic acid in a solvent;
and heating the mixture to about 55° C.

### Claim 52 (depends on 51)

The process of claim 51, wherein the solvent is selected from the group consisting of ethyl acetate, cyclopentyl methyl ether, isopropyl alcohol, and acetonitrile.

### Claim 53 (depends on 51)

The process of claim 51, wherein the mixture is stirred at about 500 rpm.

### Claim 54 (depends on 35, 52)

The process of claim 52, further comprising isolating the crystalline form of claim 35.

### Claim 55 (depends on 35, 53)

The process of claim 53, further comprising isolating the crystalline form of claim 35.

### Claim 56 (depends on 35)

A process for preparing the crystalline form of claim 35, comprising:
mixing (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide and adipic acid in a solvent;
and heating the mixture to about 80° C.

### Claim 57 (depends on 1, 56)

The process of claim 56, wherein the mixture is cooled to about 65° C. and seeded with 1 wt % of the crystalline form of claim 1.

### Claim 58 (depends on 1, 57)

The process of claim 57, further comprising isolating the crystalline form of claim 1.

### Claim 59

A crystalline form of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide comprising the following formula:

### Claim 60 (depends on 59)

The crystalline form of claim 59, having an X-ray powder diffraction (XRPD) pattern comprising an XRPD peak at 2-theta angle of 17.7°±0.2°.

### Claim 61 (depends on 60)

The crystalline form of claim 60, having an X-ray powder diffraction (XRPD) pattern further comprising one or more XRPD peaks at 2-theta angles of 7.2°±0.2°, 8.3°±0.2°, 10.2°±0.2°, 11.7°±0.2°, 11.9°±0.2°, 12.6°±0.2°, 13.4°±0.2°, 13.8°±0.2°, 14.5°±0.2°, 15.6°±0.2°, 15.8°±0.2°, 16.7°±0.2°, 19.0°±0.2°, 20.4°±0.2°, 21.1°±0.2°, 23.6°±0.2°, 25.5°±0.2°, 26.1°±0.2°, or 27.2°±0.2.

### Claim 62 (depends on 60)

The crystalline form of claim 60, having an X-ray powder diffraction (XRPD) pattern comprising XRPD peaks at 2-theta angle of 7.2°±0.2°, 14.5°±0.2°, 16.7°±0.2°, and 17.7°±0.2°.

### Claim 63 (depends on 60)

The crystalline form of claim 60, having an X-ray powder diffraction (XRPD) pattern comprising XRPD peaks at 2-theta angle of 7.2°±0.2°, 14.5±0.2°, and 17.7°±0.2°.

### Claim 64 (depends on 59)

A pharmaceutical composition comprising the crystalline form of claim 59 and a pharmaceutically acceptable carrier, diluent, and/or excipient.

### Claim 65 (depends on 64)

The pharmaceutical composition of claim 64, comprising one or more polymers selected from the group consisting of polyvinylpyrrolidone vinyl acetate (PVP-VA), hydroxypropylmethylcellulose (HPMC) or hydroxypropylmethylcellulose acetate succinate (HPMCAS).

### Claim 66 (depends on 65)

The pharmaceutical composition of claim 65, wherein the HPMCAS is selected from the group consisting of HPMCAS-L, HPMCAS-M, and HPMCAS-H.

### Claim 67 (depends on 59)

A method of treating a Bruton's Tyrosine Kinase (BTK)-associated cancer in a patient in need thereof, comprising administering to the patient an effective amount of the crystalline form of claim 59.

### Claim 68 (depends on 67)

The method of claim 67, wherein the BTK-associated cancer is selected from B-cell malignancy, B-cell lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, mantle cell lymphoma, follicular lymphoma, hairy cell leukemia, B-cell non-Hodgkin lymphoma, B-cell prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and multiple myeloma.

### Claim 69 (depends on 68)

The method of claim 68, wherein the BTK-associated cancer is chronic lymphocytic leukemia.

### Claim 70 (depends on 68)

The method of claim 68, wherein the BTK-associated cancer is small lymphocytic lymphoma.

### Claim 71 (depends on 68)

The method of claim 68, wherein the BTK-associated cancer is mantle cell lymphoma.

### Claim 72 (depends on 59)

A method of treating multiple sclerosis in a patient in need thereof, comprising administering to the patient an effective amount of the crystalline form of claim 59.

### Claim 73 (depends on 59)

A method of treating arthritis in a patient in need thereof, comprising administering to the patient an effective amount of the crystalline form of claim 59.

### Claim 74 (depends on 73)

The method of claim 73, wherein the arthritis is rheumatoid arthritis.

### Claim 75 (depends on 59)

A process for preparing the crystalline form of claim 59, comprising:
mixing (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide and camphoric acid in a solvent;
and heating the mixture to about 50° C.

### Claim 76 (depends on 75)

The process of claim 75, wherein the solvent is selected from the group consisting of ethyl acetate, cyclopentyl methyl ether, isopropyl alcohol, and acetonitrile.

### Claim 77 (depends on 75)

The process of claim 75, wherein the mixture is stirred at about 800 rpm.

### Claim 78 (depends on 59, 76)

The process of claim 76, further comprising isolating the crystalline form of claim 59.

### Claim 79 (depends on 59, 77)

The process of claim 77, further comprising isolating the crystalline form of claim 59.
